ArticleFrontiers in endocrinology2026
Exploratory analysis of mitochondrial transcription factor A as a putative biomarker for osteoporosis: a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Numerous studies have linked mitochondrial dysfunction to osteoporosis; however, the roles of mitochondrial transcription factor A (TFAM) and oxidative stress in osteoporosis are unclear. This exploratory cross-sectional study examined the relationship between TFAM, oxidative stress markers, and osteoporosis. Methods: This study included 48 participants aged 50-75, including 12 non-osteoporosis patients and 36 osteoporosis patients. Bone mineral density was assessed, and serum and bone samples were analyzed for TFAM, RANKL, OPG, BMP, SOD2, and MDA levels. Results: No significant differences in age, height, weight, or BMI were observed between groups. The osteoporosis group had higher serum MDA levels and lower SOD2 levels than the control group. Bone tissue analysis in the OP group revealed decreased TFAM and OPG expression and increased RANKL expression, with no consistent change in BMP across protein and mRNA levels. BMD was positively correlated with SOD2, TFAM, and OPG and negatively correlated with MDA and RANKL. In multiple regression, TFAM showed a significant association with BMD (β = 0.326, P = 0.005), but the model was limited by small sample size and risk of overfitting. The AUC for TFAM was 0.706 (95% CI: 0.52-0.86). Conclusion: TFAM may represent a candidate biomarker for osteoporosis, pending validation in larger, prospective cohorts. Causal and therapeutic potential should be addressed by interventional and functional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.